4.7 Review

Antiphospholipid syndrome

Journal

TRANSLATIONAL RESEARCH
Volume 225, Issue -, Pages 70-81

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.trsl.2020.04.006

Keywords

-

Funding

  1. NIAMS NIH HHS [R01 AR069572] Funding Source: Medline

Ask authors/readers for more resources

Antiphospholipid syndrome is one of the more common acquired causes of hypercoagulability. Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe preeclampsia). Classification criteria include 3 different antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, and anti-beta 2 glycoprotein I. Management includes both preventive strategies (low-dose aspirin, hydroxychloroquine) and long-term anticoagulation after thrombosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available